Home › Therapeutic areas › Immunology › Graft-versus-Host Disease
Graft-versus-Host Disease (2 companies)
Companies with an active program in Graft-versus-Host Disease.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| INKT | MiNK Therapeutics | ImmunologyOncology+1 Rare | 1 | Phase 2 | $52.8M | 8 |
| SNDX | Syndax Pharmaceuticals | ImmunologyOncology Rare | 1 | Approved | $852M | 7 |
No companies match.